Navigating the 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic Language.

CONTEXT.—: In 2022, 2 distinct guidelines for the diagnosis of myeloid neoplasms became available: the 5th edition of the World Health Organization guideline (WHO2022) solely and the International Consensus Classification (ICC). Despite major overlap, there are important differences that can have important implications.

OBJECTIVE.—: To explore the current opinions and diagnostic practices of hemato-oncologists and hematopathologists across the United States.

DESIGN.—: An online anonymous survey was created using REDCap, and a secure link was shared via email to fellowship program leadership and via posts on social media.

RESULTS.—: A total of 310 responses were obtained. Only 33 of 309 respondents (10.7%) reported using solely the 2016 World Health Organization guideline to make diagnoses, whereas 167 of 309 (54%) supplemented it with other guidelines. The rest were either not sure (17; 5.5%), used WHO2022 solely (46; 14.9%), or used ICC solely (6; 1.9%). The choice of guideline was not related to region (P = .15), practice setting (P = .86), or hospital size (P = .22). More than 90% reported having 2 distinct guidelines is a source of confusion in clinical diagnosis, management, trial design, and other areas.

CONCLUSIONS.—: Overall, our study found that having 2 distinct guidelines could be a source of confusion for physicians and it highlights the need for a unified diagnostic language.